Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2018 16:05 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease

CRANBURY, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...
June 08, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors

CRANBURY, N.J., June 08, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...
June 01, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

CRANBURY, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate...
May 30, 2018 00:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan

CRANBURY, N.J. and TOKYO, May 30, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold®...
May 09, 2018 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference

CRANBURY, N.J., May 09, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at...
May 08, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates

Continued Global Galafold® (Migalastat) Adoption and Expansion – Reaffirms FY18 Revenue Guidance of $75M-$85M at Top End of Range Significant Momentum with Pompe Clinical, Regulatory and...
April 26, 2018 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018

CRANBURY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss...
April 17, 2018 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day

CRANBURY, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is participating in several activities in April to honor Fabry Disease Awareness Month and International Pompe...
March 22, 2018 21:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan

CRANBURY, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the oral small molecule...
March 05, 2018 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018

CRANBURY, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced upcoming presentations at two investor conferences in March. John F. Crowley, Chairman and Chief...